Treatment
10
Clinical Management of Patients Taking Hormone Therapies
Monitoring During Therapy
Î For women with persistent unscheduled bleeding while taking
MHT, ES recommends evaluation to rule out pelvic pathology,
most importantly endometrial hyperplasia and cancer. (1|⊕⊕⊕
)
Î ES recommends informing women about the possible increased
risk of breast cancer during and after discontinuing EPT and
emphasizing the importance of adhering to age-appropriate breast
cancer screening. (1|⊕⊕⊕
)
Î ES suggests that the decision to continue MHT be revisited
at least annually, targeting the shortest total duration of MHT
consistent with the treatment goals and evolving risk assessment
of the individual woman. (US)
Î For young women with primary ovarian insufficiency (POI),
premature or early menopause, without contraindications,
ES suggests taking MHT until the time of anticipated natural
menopause, when the advisability of continuing MHT can be
reassessed. (2|⊕⊕
)
Stopping Considerations
Î For women preparing to discontinue MHT, ES suggests a shared
decision-making approach to elicit individual preference about
adopting a gradual taper vs. abrupt discontinuation. (2|⊕⊕
)
